Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Penny Robinson, research manager, Ipsos Immunology Monitors Drug: Obinutuzumab Company: Roche Indication: Lupus Stage: Phase III Background: Obinutuzumab is a monoclonal anti-CD20 antibody (approved as Gazyva in oncology), which demonstrated positive Phase III (REGENCY) results for lupus nephritis by significantly increasing the rate of complete renal response (CRR) to 46.4% at 76 weeks compared to placebo (33.1%)
1980 Apr;213(1):5458
Men with low testosterone are three times more likely to have the metabolic syndrome than men with higher testosterone levels
Wegovy has more cardiovascular outcomes data from the SELECT trial, which is relevant if you have established cardiovascular disease
But, I found myself stuck and unable to make a Others also viewed Similar topics Explore content categories
US$ 20.76
US$ 26.76
US$ 20.92
US$ 21.70
